Klik på linket nedenfor, tryk derefter Ctrl + C eller højreklik for at kopiere det.
Nedenfor kan du finde abstracts fra de nyeste artikler indenfor udvalgte internationale tidsskrifter med infektionsmedicinsk relevans. Du kan under "Yderligere søgekriterier" vælge tidsskrifter, hvor langt tilbage i tiden og rækkefølge.
Vælg eventuelt et eller flere søgeord til at afgrænse søgningen. Match, hvis mindst 1 ord er fundet. Benyt semikolon mellem hvert ord.
Vælg et eller flere tidsskrifter fra listen.
Alle | Ingen
Vælg hvor mange dage tilbage i tiden, der skal vælges artikler fra.
Vælg, hvordan resultaterne skal sorteres.
Ingen søgeord valgt. Opdateret for 5 timer siden.24 emner vises.
The COVID-19 pandemic has vividly highlighted how much society depends upon essential workers. Praise for the heroic work being done by health-care workers to save lives worldwide in dangerous, exhausting conditions is everywhere. But those same workers are often left unprotected by governments and systems that have failed to supply them with enough personal protective equipment (PPE), supplies, and resources to do their jobs. In April alone, there were an estimated 27 COVID-19-related health worker deaths in the USA, 106 in the UK, and 180 in Russia, with tens of thousands of infections.
Antonin Levy, Sofia Rivera
Hypofractionated radiotherapy delivers a higher dose (>2 Gy) per fraction than conventional radiotherapy, reducing overall treatment duration and associated costs. In women with early stage breast cancer, moderate hypofractionated (eg, 40–42·5 Gy per 15–16 fractions in 3–3·2 weeks) adjuvant whole-breast radiotherapy was shown to be non-inferior in terms of long-term tumour control and toxicities than the conventional schedule (50 Gy in 2 Gy daily fractions over 5 weeks).1,2 Subsequently, moderate hypofractionation has become the preferred dose-fractionation scheme for many patients.
Angus W Thomson, Amit D Tevar
On the basis of promising animal studies and following the translational path of immune cell therapy in oncology,1 the field of organ transplantation has begun preliminary investigations of infusing regulatory immune cells into graft recipients. These early trials aim to reduce patients' immunosuppressive drug burden and promote drug-free transplant tolerance. The ONE Study was established in 2011 as a multicentre collaborative effort (centres in France, Germany, Italy, the UK, and the USA) to compare the feasibility, safety, and efficacy of regulatory cell-based medicinal products (CBMPs) when combined with reduced immunosuppressive treatment in low-risk, living-donor kidney recipients.
Praveen Kumar, Nalini Singhal
India is one of the world's largest and most populous countries, made up of more than 700 diverse districts. Variations in mortality in the country are known at the macro level, and now the India State-Level Disease Burden Initiative Child Mortality Collaborators1 have mapped neonatal and under-5 mortality rates from 2000 to 2017 for every district in India, going down to geospatial grids as small as 5 km × 5 km. In The Lancet, the study authors report that the under-5 mortality rate (U5MR) in India decreased from 83·1 deaths (95% uncertainty interval 76·7–90·1) in 2000 to 42·4 deaths (36·5–50·0) per 1000 livebirths in 2017, and the neonatal mortality rate (NMR) decreased from 38·0 deaths (34·2–41·6) to 23·5 deaths (20·1–27·8) per 1000 livebirths.
Kelley Lee, Catherine Z Worsnop, Karen A Grépin, Adam Kamradt-Scott
When WHO declared the COVID-19 outbreak a Public Health Emergency of International Concern (PHEIC) on Jan 30, 2020, under the provisions of the International Health Regulations (2005) (IHR), it recommended against “any travel or trade restriction”.1 The recommendation was based on data available at the time, evidence from previous outbreaks, and principles underpinning the IHR. It formed an important part of WHO's messaging about how states could effectively respond in a coordinated way. Instead, over the following months, according to WHO, 194 countries adopted some form of cross-border measure—eg, travel restrictions, visa restrictions, border closures, among others—with little reproach from WHO or other actors in the international community.
Alexandra L Phelan
Many governments are looking for paths out of restrictive physical distancing measures imposed to control the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With a potential vaccine against coronavirus disease 2019 (COVID-19) many months away,1 one proposal that some governments have suggested, including Chile, Germany, Italy, the UK, and the USA,2 is the use of immunity passports—ie, digital or physical documents that certify an individual has been infected and is purportedly immune to SARS-CoV-2.
Anton Pozniak, Linda-Gail Bekker, Adeeba Kamarulzaman, Monica Gandhi, Richard Horton, Pamela Das, Chris Beyrer
In 2018, at the 22nd International AIDS Conference (AIDS 2018), the International AIDS Society (IAS)–Lancet Commission “Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals” laid out a bold vision for expansion of the HIV agenda with greater engagement and synergy between the movements for universal health care, non-communicable diseases, and more integrated responses to the pandemics of HIV, tuberculosis, and malaria.1,2 Our vision was challenging for many across these vital domains.
It was a tragedy for anyone hoping to see COVID-19 become a catalyst for international solidarity. On the first day of the first-ever virtual World Health Assembly, held during the worst acute global health crisis since WHO's creation in 1948, Alex Azar, US Secretary of Health and Human Services, further damaged the credibility of the US Government as a constructive member of the international community. “We must be frank”, he began. What followed was an astonishing series of unsubstantiated allegations.
President López Obrador later apologised after his comments were denounced by Mexican medical associations amid the COVID-19 pandemic. David Agren reports from Mexico City.
PPE shortages, lack of testing, and a vulnerable population have seen care homes in England and Wales become hotspots of the COVID-19 epidemic. Talha Burki reports.
As Associate Professor in Health Systems at Saw Swee Hock School of Public Health at the National University of Singapore, Helena Legido-Quigley was able to observe at first-hand how the country responded to its first COVID-19 outbreak earlier this year. “It was striking how well Singapore was prepared, a legacy from the SARS era, with a dedicated infectious diseases hospital and 6 months of supplies of personal protective equipment and ventilators. The public health response was fast and efficient with good governance and effective health-risk communication”, she says.
Among the disturbing statistics to have emerged during the COVID-19 pandemic has been the disproportionate impact in terms of death and severe illness on ethnic minorities in the UK and the USA. On April 7, 2020, it was reported that in the US city of Chicago, where the black population is roughly 30%, nearly 70% of COVID-19 deaths were in this demographic. A report released by the UK Intensive Care National Audit and Research Centre on April 17, 2020, showed that 34% of patients in the UK receiving advanced respiratory support were non-white, despite the non-white population nationally being about 14%.
Physicist turned ecologist and UK Chief Scientific Adviser. He was born in Sydney, NSW, Australia, on Jan 8, 1936, and died of pneumonia in Oxford, UK, on April 28, 2020, aged 84 years.
Shelley Riphagen, Xabier Gomez, Carmen Gonzalez-Martinez, Nick Wilkinson, Paraskevi Theocharis
South Thames Retrieval Service in London, UK, provides paediatric intensive care support and retrieval to 2 million children in South East England. During a period of 10 days in mid-April, 2020, we noted an unprecedented cluster of eight children with hyperinflammatory shock, showing features similar to atypical Kawasaki disease, Kawasaki disease shock syndrome,1 or toxic shock syndrome (typical number is one or two children per week). This case cluster formed the basis of a national alert.
Thomas A Treibel, Charlotte Manisty, Maudrian Burton, Áine McKnight, Jonathan Lambourne, João B Augusto, Xosé Couto-Parada, Teresa Cutino-Moguel, Mahdad Noursadeghi, James C Moon
The exponential growth in coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) across the UK has been successfully reversed by social distancing and lockdown.1 RNA testing for prevalent infection is a key part of the exit strategy, but the role of testing for asymptomatic infection remains unclear.2 Understanding the determinants of asymptomatic or pauci-symptomatic infection will provide new opportunities for personalised risk stratification and reveal much-needed correlates of protective immunity, whether induced by vaccination or natural exposure.
Paula M Marinho, Allexya A A Marcos, André C Romano, Heloisa Nascimento, Rubens Belfort
Coronavirus disease 2019 (COVID-19) has been shown to affect different parts of the body, and ophthalmological changes have been associated with ocular external diseases such as conjuntivitis1.
Titus Divala, Rachael M Burke, Latif Ndeketa, Elizabeth L Corbett, Peter MacPherson
Coronavirus disease 2019 (COVID-19) is now established in Africa, with more than 63 000 cases and 2200 deaths in 53 countries, as of May 11, 2020.1 Fragile health systems leave African countries vulnerable to the anticipated surge in severely ill patients with COVID-19, despite much younger populations.
Jacint Jordana, Juan Carlos Triviño-Salazar
As the EU continues to face the COVID-19 pandemic, an unprecedented transboundary crisis, its member states resort to measures within the boundaries of the nation state. This situation questions the capacity of the EU to deploy public health instruments to cope with pandemics. One such instrument, the European Centre for Disease Control (ECDC), seems to show a discreet involvement in this crisis, suggesting emerging isolationist behaviours of the member states.
Suhas Gondi, Adam L Beckman, Nicholas Deveau, Ali S Raja, Megan L Ranney, Rachel Popkin, Shuhan He
Personal protective equipment (PPE) shortages (eg, masks, gloves, gowns) endanger patients and health-care workers alike during the coronavirus disease 2019 (COVID-19) pandemic.1 Policymakers and experts have called for donations of existing PPE, increased production by manufacturers, and novel fabrication strategies, such as 3D printing of masks.2,3 However, even as PPE sources are identified, a critical information challenge remains: tracking evolving PPE needs and matching them with existing or emerging PPE stockpiles.
Clare L Whitehead, Susan P Walker
131 million women give birth annually. This population is particularly vulnerable to emerging infectious pathogens due to alterations in immune, respiratory, and cardiovascular physiology that occur during pregnancy. Recent outbreaks of severe acute respiratory syndrome, Middle East respiratory syndrome, influenza H1N1, Ebola virus disease, and Zika virus disease exposed high rates of maternal morbidity and mortality, fetal loss, and fetal harm. Early data regarding pregnancy outcomes in COVID-19 are reassuring: maternal outcomes are similar to non-pregnant adults, and vertical transmission and neonatal infection are rare.
Jenny Lumley Holmes, Simon Brake, Mark Docherty, Richard Lilford, Sam Watson
Attendance at Accident and Emergency departments in the UK is widely reported to have decreased precipitously since national lockdown was introduced on March 23, 2020. Anecdotal reports have suggested that heart attacks and strokes have “vanished from hospitals”,1 and that such patients “delay seeking help”.2 ST-segment elevation myocardial infarction (STEMI) and stroke are conditions for which hospital treatment is highly effective.
Alexandre Loupy, Olivier Aubert, Peter P Reese, Olivier Bastien, Florian Bayer, Christian Jacquelinet
End-stage organ failure is estimated to affect more than six million people worldwide.1 In 2018, transplant systems across the world enabled around 150 000 patients to benefit from a kidney, heart, lung, liver, or other solid organ—a number far less than the demand. According to data from WHO, more than 1 500 000 people live with a transplanted organ worldwide. In the USA, approximately 40 000 patients receive an organ transplant every year, but 120 000 patients remain on a waiting list for transplantation, with 7600 individuals dying annually while waiting for an organ transplant.
Adrian Murray Brunt, Joanne S Haviland, Duncan A Wheatley, Mark A Sydenham, Abdulla Alhasso, David J Bloomfield, Charlie Chan, Mark Churn, Susan Cleator, Charlotte E Coles, Andrew Goodman, Adrian Harnett, Penelope Hopwood, Anna M Kirby, Cliona C Kirwan, Carolyn Morris, Zohal Nabi, Elinor Sawyer, Navita Somaiah, Liba Stones, Isabel Syndikus, Judith M Bliss, John R Yarnold, FAST-Forward Trial Management Group
26 Gy in five fractions over 1 week is non-inferior to the standard of 40 Gy in 15 fractions over 3 weeks for local tumour control, and is as safe in terms of normal tissue effects up to 5 years for patients prescribed adjuvant local radiotherapy after primary surgery for early-stage breast cancer.
Birgit Sawitzki, Paul N Harden, Petra Reinke, Aurélie Moreau, James A Hutchinson, David S Game, Qizhi Tang, Eva C Guinan, Manuela Battaglia, William J Burlingham, Ian S D Roberts, Mathias Streitz, Régis Josien, Carsten A Böger, Cristiano Scottà, James F Markmann, Joanna L Hester, Karsten Juerchott, Cecile Braudeau, Ben James, Laura Contreras-Ruiz, Jeroen B van der Net, Tobias Bergler, Rossana Caldara, William Petchey, Matthias Edinger, Nathalie Dupas, Michael Kapinsky, Ingrid Mutzbauer, Natalie M Otto, Robe
Regulatory cell therapy is achievable and safe in living-donor kidney transplant recipients, and is associated with fewer infectious complications, but similar rejection rates in the first year. Therefore, immune cell therapy is a potentially useful therapeutic approach in recipients of kidney transplant to minimise the burden of general immunosuppression.
Northern European Conference on Travel Medicine (NECTM) 2020
Mødet udskudt på grund af COVID-19
3.06.2020 - 5.06.2020
ASM Microbe 2020
Aflyst på grund af COVID-19
18.06.2020 - 22.06.2020
Ph.d. forsvar ved Kristina Langholz Kristensen
International AIDS Conference (AIDS) 2020
6.07.2020 - 10.07.2020
International Liver Congress (ILC) 2020
27.08.2020 - 29.08.2020
COVID-19 retningslinje (2020)
National handlingsplan for antibiotika til mennesker (2017)
Retningslinjer til sundhedsprofessionelle vedr. håndtering af infektion med zikavirus (2019)
Antiviral behandling af hiv smittede personer (2019)
Ratio, rate, or risk?
28.05.2020The Lancet Infectious Diseases
Reducing transmission of SARS-CoV-2
27.05.2020Science Express TOC RSS Feed
Device-Associated Menstrual Toxic Shock Syndrome [Reviews]
27.05.2020CMR Current Issue
Taenia solium Cysticercosis and Its Impact in Neurological Disease [Reviews]
27.05.2020CMR Current Issue
Evaluation of World Health Organization–Recommended Hand Hygiene Formulations
27.05.2020Emerging Infectious Diseases Journal
Hvorfor synes Professor Jens Lundgren, at du bør læse"Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV."?
Hvad synes Professor Troels Lillebæk om"The global prevalence of latent tuberculosis: a systematic review and meta-analysis."?
Hvad synes Professor Lars Østergaard om"Efficacy of antibiotic treatment in patients with chronic low back pain and Modic changes (the AIM study): double blind, randomised, placebo controlled, multicentre trial."?
Hvorfor anbefaler Professor Thomas Benfield artiklen"Oral versus Intravenous Antibiotics for Bone and Joint Infection."?
Hvad tænker Professor Niels Obel om"Early, Goal-Directed Therapy for Septic Shock - A Patient-Level Meta-Analysis."?
Indtast din email for at tilmelde dig vores nyhedsbrev og hold dig opdateret om nyt på hjemmesiden.
© 2020 Dansk Selskab for Infektionsmedicin
version: 2.6.1 ● design: C P Fischer
Side indlæst på 0,103 s